Dr David Dodwell
David Dodwell
BSc, MD, FRCP, FRCR
Senior Clinical Research Fellow
I am a senior breast oncologist based in Leeds with a number of research and governance activities. I am the lead oncologist on the Sloane, NHS screening & national HQIP breast cancer audits.
I am a senior clinical research fellow to the EBCTCG and a member of steering groups for 12 ongoing UK trials in breast cancer. I sit on the trial management committees for 3 trials.
I am UK lead for the SACT project (UK chemotherapy database) and chair the clinical group, which provides input and advice to this project to examine the safety, efficacy and cost-effectiveness of chemotherapy used in England.
Recent publications
-
Adjuvant and neoadjuvant breast cancer treatments: A systematic review of their effects on mortality.
Journal article
Kerr AJ. et al, (2022), Cancer Treat Rev, 105
-
Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials.
Journal article
Early Breast Cancer Trialists’ Collaborative group (EBCTCG) None., (2021), Lancet Oncol, 22, 1139 - 1150
-
Breast tumour volume and blood flow measured by MRI after one cycle of epirubicin and cyclophosphamide-based neoadjuvant chemotherapy as predictors of pathological response.
Journal article
Stevens W. et al, (2021), Br J Radiol
-
Locoregional Therapy for the Primary Tumour in Women with a De Novo Diagnosis of Metastatic Breast Cancer
Journal article
Miller K. et al, (2021), Current Breast Cancer Reports
-
Treatment variation in early breast cancer in the UK.
Journal article
Dodwell D. et al, (2020), BMJ, 371